Cue Biopharma, Inc. (CUE)
NASDAQ
Cue Biopharma, Inc. EBITDA 2018–2025
Cue Biopharma, Inc. annual/quarterly ebitda history and growth rate from 2018 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Cue Biopharma, Inc. ebitda for the quarter ending March 31, 2026 was -4.8 M, a 60.76% decrease year-over-year.
- Cue Biopharma, Inc. ebitda for the twelve months ending March 31, 2026 was -42.8 M, a 14.64% decrease year-over-year.
- Cue Biopharma, Inc. annual ebitda for 2025 was -25.6 M, a 37.73% decrease from 2024.
- Cue Biopharma, Inc. annual ebitda for 2024 was -41.1 M, a 20.33% decrease from 2023.
- Cue Biopharma, Inc. annual ebitda for 2023 was -51.6 M, a 1.36% decrease from 2022.
- Cue Biopharma, Inc. annual ebitda for 2022 was -52.3 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Cue Biopharma, Inc. EBITDA — FAQ
Cue Biopharma, Inc. (CUE) ebitda over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CUE's ebitda history?
The chart and table above show Cue Biopharma, Inc.'s ebitda by year and by quarter, including the growth rate.